Introduction: In search of effective therapeutics or vaccines to treat or prevent coronavirus disease-2019 (COVID-19), various National Governments, World Health Organization (WHO), and associated partners are working on war footing to coordinate the rapid development of medical countermeasures by conducting various clinical trials. To date, several clinical trials, both Western and traditional medicines, have been registered in Clinical Trial Registry of India (CTRI). However, the relevant literature regarding clinical trials involving Ayurveda intervention on COVID-19 has not been published. In the current article, attempt has been made to extract, review, and summarize the relevant data regarding registered clinical trials under CTRI involving Ayurveda for COVID-19. Materials and methods: CTRI has been searched comprehensively for the registered trials of COVID-19 involving Ayurveda Intervention from March 01, 2020 to June 25, 2020. For each study, the CTRI registration details, demographic characteristics, and study methodology including design are collected and summarized. Results: Till June 25, 2020, a total of 58 trials were identified in CTRI, and of them 52 (89.66%) are interventional trials and 06 (10.34%) are observational trials. Majority of the registered trials are Government sponsored 39 (67.24%). Interventional prophylactic trials were found to be registered in equal proportion to the interventional therapeutic trials (26 each of the total 52 registered interventional trials). Majority of trials are controlled (35, 60.34%), and the allocation of participants into treatment or controlled groups is done by randomization in (24, 41.37%) of controlled trials. The maximum proportions of trials are open-label trials (47, 81.03%), and only three trials are double-blind placebo-controlled trials. All the intervention prophylactic trials are standalone (26, 100%); however, majority of the intervention therapeutic trials are adjunctive (17, 65.38%) to standard of care (conventional medicine). Interventional agent in most of the trials is either multiple drug combinations (23, 44.23%) or compound drug formulations (21, 40.38%) compared to single drug administration (8, 15.38%). Conclusion: The article provides an insight into the CTRI registered trials involving Ayurveda and COVID-19 till June 25, 2020. Although certain issues have been observed related to the design of trials, however, the efforts put in by various stakeholders of Ayurveda, especially Ministry of AYUSH is laudable. Once completed, the results of these promising studies should be published at the earliest, and accordingly the policy makers from Traditional system of medicines should strategize effective solutions to benefit public health in these challenging times.
Vitiligo is the most common pigmentation disorder and is described as Shwitra/Kilasa in Ayurveda due to its characteristic appearance. It is caused by the imbalance of all three Doshas (Vata, Pitta, Kapha) vitiating Rakta, Mamsa, and Medadhatus. Shwitra is harmless but a very serious cosmetic problem which affects the emotional, psychological, and social well-being of the affected person. An 11-year-old male diagnosed with vitiligo vulgaris (Shwitra), presented with complaints of increasing area and number of depigmented patches of skin which was managed by following Ayurveda principles. A treatment protocol was designed based on the signs and symptoms observed in this patient. The protocol includes Shodhana (Dipana-Pachana, Snehapana followed by Virechana), followed by Shamana treatment with a combination of powdered herbal drugs, viz., Manjishtha (Rubia cordifolia), Bakuchi (Psoralea corylifolia), Lodhra (Symplocos racemose), and Nagkeshara (Mesua ferrea) powder and Arogyavardhini Vati orally along with Bakuchi Taila (oil) for local application. The treatment protocol was found to be effective in the reversal of depigmented patches to repigmentation, which may be adopted in future cases, using different combinations of drugs based upon the different Ayurvedic parameters to obtain even better results.
AYUSH Sanjivani is a mobile application launched by the Ministry of AYUSH (MoA) to gather information regarding the utilization of AYUSH (Ayurveda, Yoga, Unani, Siddha, and Homeopathy) advocacies for the prevention of COVID-19 infection. A cross-sectional analysis of the data generated through this mobile application has been performed and presented in this article to examine the acceptability and extent of utilization of AYUSH preventive measures in India.Objectives: The objectives of this cross-sectional analysis was to determine the trends of the utilization of AYUSH measures by the beneficiaries as reported by AYUSH practitioners and by the practitioners themselves for the prevention of COVID-19 and to determine the benefit obtained in terms of self-reported parameters of general well being, the overall impact on general health and in preventing the onset of flu-like symptoms.Methods: A secondary data analysis was undertaken, utilizing the cross-sectional data generated through the AYUSH Sanjivani App from May to July 2020. The responses in terms of demographic profile, utilization pattern, benefits obtained, the interventions used and the data of beneficiaries in terms of geographic location and interventions prescribed were analyzed statistically to assess the trends of the utilization of AYUSH measures for prophylaxis.Results: Data of 74,568 AYUSH physicians and 1,35,21,245 beneficiaries/health seekers whose data were reported by 3623 AYUSH practitioners were used for analysis. AYUSH advocacies/measures were utilized by 69,195 (92.8%) physicians for prophylaxis. Samshamani Vati, Chyavanprash, and Arsenicum Album-30 were the most commonly used AYUSH interventions. Improvement in terms of appetite, bowel movements, sleep, mental well being, stamina, change in pre-existing disease, and change in disposition were reported by 42400 (61.3%) physicians. Maximum beneficiaries were from the state of Gujarat followed by Madhya Pradesh. Arsenicum Album-30 was the most commonly prescribed/distributed intervention among the beneficiaries/ health seekers.Conclusion: Maximum physicians have reported having benefited from the use of AYUSH prophylactic measures for the prevention of COVID-19. Moreover, a good proportion of the Indian population was provided the AYUSH prophylactic measures as recorded in the app.
Background: Ministry of AYUSH deals with developing education, research, and propagation of indigenous traditional medicine systems in India, and in view of public health challenge posed by COVID-19, the ministry had issued preventive and prophylactic advisories. Results and discussion: The advisories issued by Ministry comprises interventions from different AYUSH systems of medicine for preventive health measures and also for boosting immunity during COVID-19 crisis. Further, the Ministry has undertaken study through AYUSH Sanjivani mobile app for generating data of large population with a target of 5 million people. Generation of data on effectiveness, acceptance, and usage of AYUSH advocacies and measures among the population and its impact in the prevention of COVID-19 are the core expected outcomes. Conclusion: The present short communication is related to the prophylactic advisories issued by Ministry of AYUSH and details of objectives and expected outcomes of AYUSH Sanjivani mobile application developed by AYUSH Ministry.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.